Home / Transcripts / ALK-Abelló A/S (ALKB) · November 17, 2026

ALK-Abelló A/S (ALKB) Earnings Call Transcript

November 17, 2026

Nasdaq Copenhagen DK Health Care Pharmaceuticals earnings 48 min

Earnings Call Speaker Segments

Per Plotnikof executive
#1

Hi everybody, and thanks for joining this presentation of ALK's results for Q3 and the 9 months. We appreciate all of you being here. Let's go to Slide #2, where we introduce the speakers and the agenda. I'm Per Plotnikof, Head of Investor Relations, and joining me are Peter Halling, our CEO, and Claus Steensen Solje, our CFO. Peter and Claus will take you through the quarterly highlights, the markets, product trends and the financials for the 9 months. Following a brief strategy update, we'll move on to the outlook for the full year. And as always, the call will finish with a Q&A session. First, though, I'll pass things to Peter for the highlights on Slide #3. Over to you, Peter.

Peter Halling executive
#2

Thank you, Per, and thanks to everyone for making time to listen in today. In Q3, ALK achieved revenue growth of 15% in local currencies, with every region contributing. Revenue came to DKK 1,760 million, and tablets drove that growth, rising 35% to DKK 999 million, close to the DKK 1 billion level we have posted in recent quarters. Operating profit EBIT rose 9% to DKK 469 million. The EBIT margin stood at 27% versus 28% a year earlier; for the first 9 months, the margin was 28%, the same as last year; broadly, we have witnessed significant developments throughout our business since the previous call. Let me share a few highlights. The pediatric rollout is becoming an increasingly important driver of tablet growth. Pediatric launches were a major factor behind the stronger-than-expected tablet sales in Europe and Canada during Q3, and the key performance indicators stay strong. Claus will soon walk you through the regional specifics. China has the largest number of people with house dust mite allergy of any country, an estimated 100 million people, and fewer than 1 million currently receive allergy immunotherapy. The commercial potential is clearly substantial. That is why we were delighted in October to be able to announce that the Phase III trial of ACARIZAX in China met its primary objective, with efficacy and safety in line with more than 10 years of clinical data. Alongside GenSci, we are now preparing the regulatory approval filing, which we intend to submit as soon as possible in 2027. I will return to this on Slide 7. Turning to neffy, or EURneffy. Commercialization is continuing in Europe. The revenue contribution remains modest, but direct sales in Europe and Canada grew roughly sixfold in Q3. The launch in Canada and the launch of the 1-milligram version in Germany look promising; we also signed a partnership with Zuellig Pharma to bring neffy to selected Southeast Asian markets; in September, we announced an expanded partnership with Catalent, giving us strategic supply robustness. It also secures long-term access to Zydis tablet technology for all our allergen products and raises our prioritized tablet capacity by 40%. This expanded partnership supports the long-term growth we are planning for ALK. In food allergy, we are moving forward with preparations to start the pivotal Phase III trial of our peanut tablet before the end of the year. Lastly, on October 7, we upgraded our full year outlook on the strength of the tablet momentum. And today, we confirm that outlook. All in all, Q3 was a good quarter for ALK, with financial and strategic progress. I will now hand over to you, Claus, for the regional trends on Slide 4.

Claus Solje executive
#3

Thanks, Peter. During the third quarter, every one of our three sales regions delivered growth, and Europe continued to lead the way. Revenue in Europe increased 18% at local currencies, and tablets were the main driver behind that increase. Sales of tablets were up 33%, mostly from higher volume linked to the surge of patients during the '25 and '26 initiation season. This year's initiation season is still at an early stage, but it appears robust for ITULAZAX, the tree tablet, and a bit more modest for GRAZAX, the grass tablet. In addition, we have observed solid progress throughout the year in new patient initiations for ACARIZAX, the house dust mite tablet. The children adolescent indications are adding increasingly to growth, and we are likewise noticing indications of improved treatment adherence among this patient segment. Each of our tablet products posted double-digit gains, led by the tree pollen tablet ITULAZAX. One thing worth flagging: reported sales got a lift to some degree from wholesaler stocking variations, which included advance stocking before the main initiation season here in Q4. In Germany — the biggest allergy immunotherapy market in Europe — tablet sales rose substantially. We also saw strong growth throughout Central and Eastern European countries, and the U.K. posted high growth, though it started from a smaller base. As you're aware, Germany's mandatory rebate increase kicks in on 1st of January 2027, and we're carrying out an internal action plan aimed at offsetting that impact. Sales of injection-based SCIT combined with drop-based treatment were up 3%. SCIT posted a modest gain, and SLIT drop revenue stayed level. Fewer patients beginning SCIT and SLIT drops treatment—opting instead for tablets—continue to weigh on underlying growth. European sales of Anaphylaxis and other products fell 1% to DKK 111 million. That figure reflects an unusually strong Q3 a year ago tied to Jext share gains and tender wins throughout the region; beyond that, the U.K. saw a much larger volume of Jext expiries during last year's Q3, which lifted refill revenue at the time. EURneffy sales rose roughly 250% during the quarter, driven mainly by Germany, though the numbers are still modest since the product is in the early stages of launch and market access work is underway in many markets. North American revenue climbed 8% in local currency, reaching DKK 270 million. Tablet sales were up 32%, largely because of Canada, which keeps posting strong sustained growth with help from the pediatric rollout. The U.S.A. also recorded double-digit growth, aided by stepped-up promotional efforts. SCIT bulk allergens extract sales, mainly to U.S. allergists, were flat, as somewhat lower volumes were offset by higher prices. Anaphylaxis and our other products posted 2% growth, helped by neffy's initial sales in Canada. Certain PRE-PEN back orders held back sales of other products, and we expect those to be resolved later this year; internationally, revenue climbed 6% in local currencies, reaching DKK 248 million. The driver was a jump in tablet shipments to Japan, where in-market sales are accelerating, particularly for our CEDARCURE tablet, thanks to a stronger supply of active pharmaceutical ingredients from Torii's new manufacturing facility. Tablet revenue in that region increased 47%, reflecting product shipments and sales royalties from Japan along with growth across most of the minor market in Southeast Asia. Sales of SCIT and SLIT drops totaled DKK 47 million, compared with an unusually high level of SCIT shipments to China in Q3 of last year, which came after we renewed the import licenses we had obtained there; in China, GenSci's commercialization of our SCIT products and skin prick test continued to make progress. In-market sales were temporarily affected by the partner transition, although growth has picked up recently. Now let's turn to Slide #5 and the product lines. Tablet sales worldwide increased 35% to DKK 999 million, equal to 57% of group revenue. That is essentially consistent with the roughly DKK 1 billion level seen in Q1 and Q2, and growth was increasingly driven by the pediatric rollout. Tablet sales in Europe grew 33%, with North America at 32% growth and international markets at 47%. Combined SCIT and SLIT drop revenue declined 6% to DKK 527 million, representing 30% of revenue. As I noted earlier, this decrease resulted from normalized shipments to international markets. Anaphylaxis and other product sales increased 1% to DKK 238 million, accounting for 13% of revenue. neffy direct sales rose sixfold, though from a small base, which reflects the early stages of market launches while reimbursement is still pending across many markets. Moving on to Slide 6, let's look at the financials. Over the nine-month period, local-currency revenue increased 17%, reaching DKK 5.3 billion, with tablets, Anaphylaxis and SCIT products fueling that growth. Reported revenue growth took a 1-percentage-point hit from exchange rates, largely because the U.S. dollar weakened. Gross profit came in at DKK 3.6 billion, a gross margin of 68% versus 67% a year earlier; the improvement stemmed from greater sales volumes, production efficiencies and a sales mix carrying a comparatively larger share of ALK's high-margin direct product sales relative to lower-margin partner sales. Capacity costs climbed 20% in local currencies to DKK 2.1 billion, reflecting substantial growth investments. R&D spending climbed 24%, reaching DKK 516 million, with the increase largely tied to clinical work on the peanut tablet and our preclinical programs. On sales and marketing, we spent DKK 1.3 billion, a 20% increase, reflecting what we've put behind the pediatric tablets and neffy launches — more sales personnel as well as dedicated marketing campaigns. Administrative costs came in 18% higher at DKK 301 million, which stems from expanding the organization, constructing the infrastructure needed for growth, and an overall very high level of activity. One point we want to emphasize: we do not anticipate any further cost step-up as we move ahead. As we look toward the coming year, our plan calls for a significantly more modest rise in the cost base than what we saw in 2026. Turning to operating profit, it rose 16% in local currencies, reaching just under DKK 1.5 billion. The EBIT margin held steady at 28%, since the better gross margin was offset by a somewhat higher ratio of capacity cost to revenue. Net financials recorded a gain of DKK 33 million tied to interest income and currency gains. Net profit climbed to DKK 1.1 billion. Free cash flow came in at DKK 1.19 billion, compared with DKK 836 million previously, helped by stronger earnings and shifts in working capital. For Q3 on its own, free cash flow totaled DKK 303 million, while the net debt-to-EBITDA ratio stayed negative at 0.7. Overall, it was another quarter of robust growth and a sound financial position. Let's now move on to Slide 7, covering execution of the Allergy Plus strategy. Peter, over to you.

Peter Halling executive
#4

Thanks, Claus. I'll walk you through where things stand with Allergy Plus, beginning on the respiratory allergy side. Our pediatric tablet launch keeps driving more new patients into the franchise and widening the prescriber base. As of the close of Q3, the house dust mite tablet had gained pediatric approval across 36 countries, with launches completed in 24 of them, France being the latest to come on board. For the tree pollen tablet, ITULAZAX, approvals for children and adolescents now cover 20 countries, and it has been launched in 14. Our key performance indicators are still solid, among them patients started on treatment, endorsements from key opinion leaders, caregiver engagement, and doctor visits. In China, as I mentioned earlier, the ACARIZAX Phase III trial met all of its primary objectives successfully. Results favored ACARIZAX over placebo, with a relative difference of 19.1%. Execution of the trial was strong and treatment compliance was high; we will now work alongside GenSci on the approval filing, which we expect to submit as soon as possible during the first half of '27. If approved, a launch could potentially happen toward the end of '28, and ACARIZAX would then join GenSci's portfolio; we are very pleased with these results and view our partner as highly committed. So this is a good sign for our future in China. To underpin long-term tablet growth, we have broadened our partnership with Catalent. This agreement locks in access to Zydis technology across all of our allergen products and lifts our prioritized tablet capacity by 300 million tablets, roughly 40%, taking us to 1.1 billion tablets annually from the early 2030s, drawing on sites in the U.K. and in Canada; we will make payments of approximately DKK 500 million over 3 years, which get capitalized on the balance sheet and amortized across the contract term. Moving to Anaphylaxis. At the end of September, the 2-milligram version of neffy for adults and for children weighing 30 kilos or more had been launched in 14 markets, while the 1-milligram version for children was launched in Germany. Early feedback on the 1-milligram version in Germany is encouraging. The 2-milligram neffy version launched in Canada in late July and has delivered good coverage and traction among healthcare providers, prescribers and patients. Canada and Germany were the biggest revenue contributors in the quarter, and we still expect those markets, together with the U.K., to lead long-term growth. Recently, Canadian pharmacy regulators classified neffy as a Schedule II product throughout Canada, meaning it will be available without a prescription in areas where one was previously required. In the U.K., formulary access keeps moving forward, albeit slowly, which reflects the ongoing healthcare reform and administrative processes there. We have recently partnered with Zuellig Pharma in Asia Pacific to bring neffy to selected Southeast Asian markets, including Singapore, Thailand, the Philippines, Malaysia, Indonesia and Vietnam. Zuellig will sublicense neffy from ALK, and subject to regulatory approval, neffy could become available in those markets within a few years. Finally, let me turn to food allergy and our new disease areas. We’re making headway on preparations for the pivotal Phase III study of our peanut tablet. The clinical trial application, CTA, has been filed with U.S. FDA, and at this point we’re waiting to hear their feedback on it before the trial can get underway. Our biologic candidate, ALK014, which targets the IgE axis of the immune system, is still moving toward clinical development in '27. And lastly, interim data from the Phase IIb trial of neffy in acute flares of chronic spontaneous urticaria, or CSU, remains on track to arrive in the first quarter of '27. Also, through our agreement with ARS Pharma, we hold exclusive rights to neffy for this indication and other new ones within the license territory; with that update, I’ll turn things back to you, Claus, and the full year outlook on Slide 8.

Claus Solje executive
#5

Thank you, Peter. Back on 7 October, we raised the outlook for the entire year, a move that reflected the robust sales momentum for tablets across our regions. That outlook is confirmed today. Revenue is now expected to increase between 16% and 17% in local currencies, compared with the earlier range of 14% to 16%, driven by growth in every sales region and product line, with tablets the main driver. We expect an EBIT margin of roughly 27%, versus 26%, largely reflecting operating leverage stemming from the higher revenue outlook. Volume will be the predominant source of that growth. Tablet sales should rise by double digit in all regions, and children and adolescent are projected to make up a larger share of sales. For combined SCIT and SLIT drop sales, single-digit growth is anticipated, while Anaphylaxis and other products are projected to rise by low double digits, with neffy making a modest contribution. The gross margin should come in slightly above last year's 67%. Favorable volume and mix changes will benefit that margin, particularly higher tablet sales in Europe, partly offset later in the year by growth in lower-margin partner-related revenue, mainly shipments to Japan and China plus neffy sales. Capacity costs remain projected to rise, and their ratio to revenue should be largely on par with last year's, since we are reinvesting the benefits of scale into key growth opportunities and R&D. R&D is expected to come in slightly above 10% of revenue. CapEx is projected at approximately DKK 400 million, and free cash flow is now expected to surpass DKK 1.1 billion; so to sum up, momentum in the business is strong. We are well positioned to keep delivering more than 10% growth in the years ahead while also generating attractive shareholder returns. With that, I will hand it back to you, Per, and to Slide 9.

Per Plotnikof executive
#6

Thanks, Claus and Peter. That brings our presentation to a close, and we'll open the Q&A session now. Operator, please go ahead.

Jesper Ingildsen analyst
#7

I have three questions, and I'll ask each one separately, if that's alright. Maybe first, regarding the impressive European tablet growth of 33% that you recorded this quarter, I'm just trying to understand what drove that here in Q3 and also what to expect as we move into Q4 and next year. So you brought up the wholesale stocking effect — could you help us understand how much of a contribution that made during the quarter and whether we should anticipate a reversal in Q4? And when it comes to European growth, you brought up children — the children launch continued to be a significant factor behind that robust growth. I think during Q2 you said that new patients — new children — accounted for about 30% of prescriptions that quarter, versus your goal of 50%. Can you bring us up to date on that? And finally, on the tablet growth — could you say a bit more about whether Q3 gets any lift from the initiation season, and more specifically what you've observed so far this initiation season? As I recall, at this same point last year you mentioned growth of plus 10% — actually well above 10% — in new patient starts for the tablets in Europe. That's my question about tablets. I'll come back afterward with two more questions.

Peter Halling executive
#8

Thanks, Jesper. So, three questions. For question 1A, though, I'll pass that to Claus regarding European tablet growth, and I'll take question 1B and C myself.

Claus Solje executive
#9

Yes. Thank you, Jesper. Let's see whether we can work this one out. So Peter will address part of it. And I would just add this regarding the stock — the wholesaler stocking, as you mentioned. It's true that when Peter comes back and talks about the initiation season, he can add where we see that. But we expect a fairly good initiation season; and that also means we have actually seen some wholesaler stocking here in Q3 among many of our wholesalers across Europe that is kind of ready for the Q4 initiation season. To give some numbers, what you can roughly count on is around DKK 20 million to DKK 30 million. But it's important to say there are a lot of fluctuations this quarter, which was the same last year, if you recall. So it's hard to put a precise number on it; but use around DKK 20 million to DKK 30 million that you have seen here that is a stock buildup that probably would belong to Q4. And then I will leave it to Peter for the initiation season.

Peter Halling executive
#10

Yes, we can go ahead. So, Jesper, on your first question—sorry, your second one, about children—that segment keeps powering the business. You're correct that we mentioned the 30%. What we observe is that this is carrying on and rising in a positive way. We aren't disclosing the figures, but the 50% long-term objective is still in place, and it's genuinely encouraging to see launches backing that objective. So overall, things look good on children and are above the 30% threshold on the way to 50%. On the tablet initiation season, perhaps I can break that down. Starting with grass, it has been fair and at a sensible level. Thus far, it's what we'd describe as a more normal season at that level. Tree initiation has been very solid for us, especially when it comes to birch and the other tree types that matter for ITULAZAX. That is another positive driver as well. House dust mite then carries on, though as you're aware, for us that is more of an all-year item. So perhaps just on that point—overall, with tablets, I believe we keep witnessing solid progress right across the board. So, question 2. Jesper?

Jesper Ingildsen analyst
#11

Yes. Sorry. Yes, question 2 would be about Germany. So you point out once more that you're carrying out internal action plans to soften the rebate increase starting 1st of January. You spoke about that before. Could you update us? And also in early October you mentioned some possible exemptions regarding having some of your production or patients located in Germany. Any news on that specifically?

Peter Halling executive
#12

Yes. Thank you, Jesper. This is Peter. I think at best, we can say the political environment in Germany remains opaque. It is not 100% clear there is still, and we're examining what are basically the options we have in Germany. A great deal of conjecture exists about the outcome and about what is feasible legally and under EU regulation. So my view is that the answer isn't known yet. We remain convinced that what lies within our control is clearly the cost side, and also certainly how we engage with the insurers — that work continues, and it is advancing according to plan. Put differently, our numbers essentially assume we will have the full rebate, and beyond that there is upside. Even so, we keep hoping, and we keep working on the possibilities in that area. What will actually become law, however, is unclear at this point. I realize that response isn't very specific, but it's the most I can offer right now.

Jesper Ingildsen analyst
#13

And for the final question, I'd like to ask about the corporate tax reform proposal that recently came up in Denmark, which as I understand it might lower the rate from 22% down to 19%. I'm just curious what the implications of that would be for you, since your effective tax rate at present sits closer to 24%-25%. I'm wondering roughly how much of your profit is taxed in Denmark right now and then, yes, how low your effective tax rate could actually go as a result of this?

Peter Halling executive
#14

Yes. Claus?

Claus Solje executive
#15

Yes. Thank you, Jesper. You're correct that, of course, at this point they still need to get it passed through parliament. Still, broadly speaking, it's encouraging to see politicians backing the business climate, and naturally that will also be beneficial for investments, particularly in Denmark. We're actually in a position where a great deal of our profit across many of our therapy areas is in fact generated in Denmark and taxed there; so that also means it has a fairly favorable effect on our effective tax rate. As we calculate it at the moment, and you're right, we're at roughly 24% to 25%, we then expect that once it's fully in place we could come all the way down to approximately 21% for our effective tax rate. Of course, we'll have to wait and see when it gets implemented and how things will look and all the specifics, but it will be a fairly substantial positive effect that we, of course, think is good for Denmark as well, since it gives us a chance to keep up our investment into ALK.

Thomas Bowers analyst
#16

Yes. Let's take Germany, and I'll set the rebate question to one side. What I'm really asking about is the shift away from those unregistered allergen products. You said earlier that you expect it to be largely finished by year-end, so I'm curious how we should view the effect on '27. Have most patients moved over to the registered product by now? Or is there still a meaningful tailwind to capture from the remaining part of that transition as we go into '27? Then my second question concerns ACARIZAX in China, following the positive Phase III readout. On the regulatory filing, I just want to confirm: will it cover adults only? And have you had any dialogue with the authorities about the pediatric indication — whether it can be included, or whether you'd need another bridging Phase III-type study in order to include it and broaden the label? And finally, on Japan, with SeouLin taking over the ACTHAR product from February '27: is there anything you can tell us ahead of that February '27 date? Is there anything suggesting we should already expect a positive effect from early '27?

Peter Halling executive
#17

Thank you, Thomas. I'll begin, and then Per and Claus can come in on the 3 questions. Starting with Germany and the TAV: the short answer is that this transition has been underway and it still is. You continue to see regulatory approvals arriving at the tail end. So we do have competitors bringing in 1 or 2 products. You also have patients who've been started on and remain on the products. So I'd say we still expect an impact, though I'd put it at less than 10% of patients that are essentially in play here; that said, we think we're very well positioned in Germany to capture part of that portfolio, and as you know we currently hold a fair market share in Germany that we believe we can keep building. So that's clearly a patient pool we remain interested in within Germany. On ACARIZAX in China, you're right, it's for adults. And we'll need to have a dialogue with the Chinese authorities about how they see it for children. But we don't know where they stand, and that discussion will be facilitated not by ALK but by our partner, GenSci. Still, I can tell you both companies will be very keen to expand, so we make sure of that. So at this stage there's no clear path as to whether additional studies are needed or whether the data suffices to support it. That would of course be a matter for discussion. Now, regarding Japan and specifically Shionogi plus the takeover involving the MA divestment, we are seeing a really strong commitment from Shionogi. They are very eager to make progress in Japan, and we stay confident this will be a very solid partnership for both sides. Having said that, this obviously goes to competition. But I would note that in my view Shionogi, Torii and ALK together hold a strong position in Japan, and we expect opportunities exist in the Japanese market to keep gaining share going forward. So I think that is about all I can say on that. And then you are right, we will have to see once the MA has been transferred. So did that answer your question, Thomas?

Thomas Bowers analyst
#18

Yes. That's great.

Sandrine Verweij analyst
#19

Sandrine here, filling in for Sushila. So, a bit more on the sales growth. Could you give us some insight into how you anticipate market share will improve over the coming 6 to 12 months? And then perhaps a second question about neffy. Could you elaborate somewhat on the launch you're seeing in Canada and Germany, and what's required for this to become a meaningful contributor to ALK?

Peter Halling executive
#20

Thank you, Sushila. I think particularly regarding the second question, could you repeat it? It cut out a bit on our end, and it was about neffy.

Sandrine Verweij analyst
#21

Yes; so regarding the second question about neffy, could you just elaborate on the launch in Canada and Germany and on what you believe is required for this to become a meaningful contributor to ALK?

Peter Halling executive
#22

So I'll begin with market share. As you know, each year, as part of the annual report, we share our perspective on where we stand in the market; we believe, based on the figures we have and what we observe, that we keep gaining market share across most markets; and we are positioned, if things continue as they are, to also outperform with respect to overall market progress globally. So I think the answer to your question is that we expect and see opportunities to still gain market share. Right now, we are at roughly the 50% mark, plus/minus, but we expect that to continue; and that also indicates that ALK not only has a position where we can grow from our business and expand the market through prescribers and patients, but actually also that we can gain market shares that can be meaningful contributors to our growth going forward; on neffy, then Claus, would you like to add a few points?

Claus Solje executive
#23

Absolutely. Thanks for that question, Sandrine. Let me begin with Canada and Germany, since those are 2 key markets for the neffy business as a whole. In Canada, it's naturally still early. We brought neffy, the 2-milligram, to market in late July, but I can say the launch has gotten off to a rather encouraging start, and uptake and traction with healthcare providers, prescribers, and patients have in fact been quite favorable. There are 3 areas we're watching closely, and on all of them we stay optimistic. First comes access. Reimbursement is admittedly still being established, yet we have robust patient support programs in place to help with access and cost barriers, so we view that positively. Second is engagement: we're getting very strong backing from healthcare professionals as well as patients, and that has been true from day 1, so support is broad across the country and engagement is high. Third is the pharmacy channel, which Peter mentioned earlier when we opened the session, and that will be interesting. The new Schedule II classification means that where a prescription used to be required, you can now go without one, and when you visit the pharmacy to collect your second neffy, you no longer need a fresh prescription. That's a new development, and we think it will prove very positive, so overall, in Canada we regard this as a very encouraging start. Naturally, we now need to see the data arrive, but at present we view it positively. Turning to Germany, we've launched the 1 milligram there, and we're fairly comfortable with what we've observed. The 1 milligram is particularly associated with children. Once again, we can conclude that the allergy space overall, and anaphylaxis in children too, is very important. Here as well we're seeing favorable progress, though of course it's early days. So we feel quite good about these 2 concrete items. If this unfolds the way we expect, and likewise in the other markets, particularly across Europe, for neffy, then next year we should begin to see neffy contributing to the numbers, and you'll be able to see those. I hope that gives you a sense of the neffy picture.

Peter Ankersen analyst
#24

Peter Hugreffe here from Nordea. Claus, this one's directed at you, and I just want to get clear on what you're saying about the cost base for 2027. I picked up something about a modest cost increase. Could you walk us through the underlying elements there? Because the last time I checked, at least, you guys were expecting growth in R&D specifically. So please help us understand that piece. Second, this may also be for you, Claus, regarding the cash position. Right now you're at DKK 1.5 billion. And I can see you have very healthy cash flow. So I know there's a chance I sound like a broken record, but could you just help me understand your thinking on when it's enough? You've heard that before; and when should we expect some kind of insight into that? And just as a sidebar to that one, I think you guided for DKK 1.1 billion for this year, and you're at DKK 1.2 billion; so how should I think about that? And then finally, just on peanut, what's in the CTA in terms of drug design — trial design? Any light you could share on that would be appreciated.

Peter Halling executive
#25

Thank you, Peter. I think, Claus, you are on.

Claus Solje executive
#26

I'll take the first 2 questions. Thanks, Peter. Yes, allow me to shed a little more light on the cost side. What we're essentially saying is that after a number of years in which you have, of course, been following this, our investment rate was quite low, roughly an average of 4% to 5% growth in our cost base year-on-year, also in order to reach the 25% EBIT margin in '25; then there is no question that '26 has been a year in which we have stepped up our investments, both in the commercial area and in R&D, but also in administrative costs, particularly building infrastructure, scaling the company and so forth; and that is why you have been seeing these roughly 20% capacity increases in our cost here during the first 9 months. You'd likewise notice a pretty meaningful bump in Q4. Looking forward, my point is just that you shouldn't assume we'll keep up that same percentage pace next year. We've made a step up in '26, and cap cost will still rise next year, just not as much as this year's roughly 20%. So really we're just signaling: don't count on two years in a row of a 20% cap cost increase — that's all I meant by that. That doesn’t mean cap cost increases have stopped. We’re continuing to put money into the commercial side and, naturally, particularly into R&D with the peanut next year. On the cash position—feel free to repeat yourself like a broken record. That’s fair enough. You’re correct that cash is building up. We’re aware of it, and we’re in a solid spot, especially with this. We’ll keep exploring various opportunities on the BD side, and our policy remains the same: invest in organic growth. We've now put money into the Catalent expansion that Peter mentioned as well. And we're still examining BD&L opportunities. But like we said in August, we'll keep exploring those business development opportunities across the various therapy areas. But we're also looking at what we'd do with the cash if this doesn't come together. And we intend to present a plan for that, and that will likely be better later on, around the full year announcement. So that's what we expect to do there.

Peter Halling executive
#27

Good. And then perhaps regarding China CTA, Per, would you like to say a few words?

Per Plotnikof executive
#28

Regarding the peanuts program in the U.S., yes, there isn't much detail we can provide right now, Peter. So, following our end of Phase II conversations with the regulators, we've taken their feedback on board and submitted the CTA. At this point we're awaiting their response, and after that we can move forward. Once that feedback arrives, we'll also be able to walk you through the specifics of the study design. Naturally, it's built on the Phase II. But before we receive the feedback, we need to determine whether everyone in the room is fully aligned, so we can be transparent about how it looks. Still, it's super exciting, and we're looking forward to sharing that with you, hopefully in the next few weeks, before Christmas.

Peter Halling executive
#29

I want to be clear that when I said China, I was referring to peanuts. So let me make that absolutely clear.

Hakon Hemme Jørgensen analyst
#30

I have two questions, please. First, on the pediatric launches in Q1, you said there were over 4,000 pediatric prescribers, and roughly 4,500 in Q2. Those numbers, though, weren't refreshed in this Q3 report. Could you update us on that figure? I was wondering whether prescriber recruitment is starting to plateau, with growth coming more from additional patients per existing prescriber, or whether there's still substantial room to expand the network. Then, on Anaphylaxis, where performance appears to be normalizing more now following last year's strong market share gains for Jext: how would you describe competitive intensity in the adrenaline market today, for both Jext and EURneffy? Have you noticed any changes in pricing, competition or how prescribers behave, or anything that impacts your capacity to hold share and grow EURneffy adoption?

Peter Halling executive
#31

Thanks. I believe I can cover both of those points. On the pediatric side, when it comes to actually tracking how many new prescribers there are and so on, we've made a decision. It gets harder as we grow. Still, the key point is that we are adding. I'd call that a positive as we move into new markets and, even in the ones we already serve, we keep seeing progress. I believe we'd be more at ease discussing particular figures once we've completed the yearly conversations with our commercial excellence teams and so on; but in brief, Hakon, we keep observing progress. And clearly, in new markets, it's even greater than what we're seeing in the ones that already exist. So that's encouraging. Regarding Anaphylaxis, please keep in mind, there are a few distinct factors. First, when we examine the markets, we need to split out the tender business, which is an extremely competitive segment. But for one product category, the auto-injectors, that's primarily in Northern Europe, and also portions of Italy and so forth, where that tender business exists. We've been involved in that business for a great many years. In France, Spain, the U.K., and other markets, pricing is actually determined on a cross-market basis. You've got negotiations going on continuously there, and on top of that you have price conversations with the government. What's interesting is that in a few of those markets, we've seen prices go up over the past few years, which has benefited us, and that's still happening. It comes down to supply and demand. So yes, it's a fiercely competitive market. Supply plays a big role, as do some of the supply disruptions that have been occurring in those markets. But I genuinely believe our gain has come from getting our supply situation stabilized. Our supply position is pretty solid, though we also picked up some tenders. And because shelf life factors in, you're not really comparing year over year; in fact, for Jext the shelf life can range from 14 to 22 months in some cases. Some of what you observed in the U.K. shows up in those figures too. That makes it a bit trickier for us to talk about it specifically quarter over quarter, and that's just the way that market operates; as for neffy, neffy is an entirely different situation. Sure, there's competition, you might say, from patients already using auto-injectors whom we're trying to switch over; however, we're also noticing that neffy brings its own value, both regarding shelf life and definitely when it comes to how easy it is to use and the solid product features that matter particularly for younger kids, as well as teens and adults; so we truly see neffy having a significant part in growing the markets, and that's what we keep observing in several other markets too. In short, our established anaphylaxis business—Jext and the auto-injectors—is a space we've observed before and one that remains competitive. Neffy has a role both in converting patients and in growing the market. Overall, things are largely in line with what we anticipated, and we expect that to carry on over the next several years. As we also mentioned, double-digit growth is definitely something we could see ahead as well. So we stay fairly optimistic about how the anaphylaxis portfolio will develop for us going forward. That was a long answer, but I hope it gave you some clarity.

Per Plotnikof executive
#32

Great. Thanks to everyone for the usual round of solid questions. Now, just before we wrap up this call, I’d like to point out a few investor events coming up. In addition to that, our annual report for ’26 will be released on 9 February ’27. With that, we hope to see you on the road, and we’ll bring today’s session to a close. Have a good day, everyone. Thank you. Goodbye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete ALK-Abelló A/S transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.

Get an API key View API docs →

For developers and AI pipelines

Programmatic access to ALK-Abelló A/S earnings transcripts and 132,000+ others is available through the EarningsAPI REST API and the hosted MCP server. Quarterly plans from $162 - full transcripts, speaker segments, full-text search, and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.